A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2018
At a glance
- Drugs Daprodustat (Primary) ; Darbepoetin alfa; Darbepoetin alfa
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms ASCEND-ID
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2018 Planned End Date changed from 15 Nov 2019 to 5 Jun 2020.
- 01 Mar 2018 Planned primary completion date changed from 15 Nov 2019 to 5 Jun 2020.